Novonesis (Novozymes) B (NSISBC.XD)
DKK 410.0
(-0.89%)
DKK 410.0
(-0.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.63 Billion DKK | -1.56% |
| 2022 | 5.72 Billion DKK | 13.04% |
| 2021 | 5.06 Billion DKK | 7.7% |
| 2020 | 4.69 Billion DKK | 2.51% |
| 2019 | 4.58 Billion DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.12 Billion DKK | -7.19% |
| 2024 Q2 | 1.12 Billion DKK | 0.0% |
| 2023 Q2 | 1.34 Billion DKK | -13.55% |
| 2023 Q4 | 1.21 Billion DKK | -19.99% |
| 2023 Q1 | 1.55 Billion DKK | 50.29% |
| 2023 FY | - DKK | -1.56% |
| 2023 Q3 | 1.51 Billion DKK | 12.63% |
| 2022 Q3 | 1.69 Billion DKK | 0.0% |
| 2022 FY | - DKK | 13.04% |
| 2022 Q4 | 1.03 Billion DKK | -38.88% |
| 2021 FY | - DKK | 7.7% |
| 2020 FY | - DKK | 2.51% |
| 2019 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|